Kinaset Therapeutics is focused on creating inhaled, anti-inflammatory medicines for serious respiratory conditions. Its lead candidate, frevecitinib, is a dry-powder, single-capsule pan-JAK inhibitor (JAK1/2/3, TYK2) designed to deliver therapeutic lung concentrations while minimizing systemic exposure. The drug targets both Th2- and Th1-driven disease, giving it potential efficacy across the broad severe asthma population, including patients with non-eosinophilic phenotypes who currently lack effective options. Early clinical data have demonstrated promising safety and pharmacology, and proceeds from the latest financing will fund a Phase 2 dose-ranging study in severe asthma patients. By overcoming historical drug-delivery challenges for inhaled JAK inhibitors, Kinaset aims to provide the first novel, inhaled anti-inflammatory mechanism for asthma in decades. The company operates from Boston and is supported by a syndicate of leading life-science investors.

Total raised

$143M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2026